This exploratory study investigated meaning in life (MiL) in patients with progressive supranuclear palsy (PSP). In the “Schedule for Meaning in Life Evaluation” (SMiLE), respondents list individual MiL areas before rating their current satisfaction and importance with them (index of weighting [IoW], index of satisfaction [IoS], and index of weighted satisfaction [IoWS], range 0-100). A total of 38 patients with PSP completed the SMiLE (IoS: 68.6 ± 25.6, IoW: 79.6 ± 12.6, and IoWS: 69.2 ± 26.1). A representative sample of healthy participants (n = 977) scored significantly higher in the IoS (82.8 ± 14.7, P < .001), the IoW (85.6 ± 12.3, P = .006), and the IoWS (83.3 ± 14.8, P < .001). Compared to healthy individuals, patients with PSP were less likely to list health (P = .001) and more likely to list partner (P = .04), leisure (P = .01), home/garden (P = .01), and pleasure (P = .02). Patients with PSP seem to focus on supportive relationships and leisure, while the decreasing health status is becoming less important to them.
BensimonGLudolphAAgidYVidailhetMPayanCLeighP. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS Study. Brain. 2009;132(1):156–171.
2.
LudolphAKassubekJLandwehrmeyerB. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16(3):297–309.
3.
LitvanIBakerMHuttonM. Tau genotype: no effect on onset, symptom severity, or survival in progressive supranuclear palsy. Neurology. 2001;57(1):138–140.
4.
GoetzCLeurgansSLangALitvanI. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology. 2003;60(6):917–922.
5.
SchragABen-ShlomoYQuinnN. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354(9192):1771–1775.
6.
LitvanI. Atypical parkinsonian disorders. Movement Disord. 2004;10(3):42–64.
7.
FolkmanSGreerS. Promoting psychological well-being in the face of serious illness: when theory, research and practice inform each other. Psychooncology. 2000;9(1):11–19.
8.
BreitbartWRosenfeldBPessinH. Depression, hopelessness, and desire for hastened death in terminally ill cancer patients. JAMA. 2000;284(22):2907–2911.
9.
BreitbartWRosenfeldBGibsonC. Meaning-centered group psychotherapy for patients with advanced cancer: a pilot randomized controlled trial. Psychooncology. 2010;19(1):21–28.
10.
LeeVCohenREdgarLLaiznerAGagnonA. Meaning-making intervention during breast or colorectal cancer treatment improves self-esteem, optimism, and self-efficacy. Soc Sci Med. 2006;62(12):3133–3145.
11.
ChochinovHKristjansonLBreitbartW. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol. 2011;12(8):753–762.
12.
O'BoyleC. Making subjectivity scientific. Lancet. 1995;345:602.
13.
FeggMKramerML'hosteSBorasioG. The Schedule for Meaning in Life Evaluation (SMiLE): validation of a new instrument for meaning-in-life research. J Pain Symptom Manage. 2008;35(4):356–363.
14.
StiefelFKrenzSZdrojewskiK. Meaning in life assessed with the “Schedule for Meaning in Life Evaluation” (SMiLE): a comparison between a cancer patient and student sample. Support Care Cancer. 2008;16(10):1151–1155.
15.
FeggMBrandstätterMKramerMKöglerMHaarmann-DoetkotteSBorasioG. Meaning in life in palliative care patients. J Pain Symptom Manage. 2010;40(4):502–509.
16.
FeggMKöglerMBrandstätterM. Meaning in life in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(5):469–474.
17.
SchragASelaiCDavisJLeesAJahanshahiMQuinnN. Health-related quality of life in patients with progressive supranuclear palsy. Mov Disord. 2003;18(12):1464–1469.
18.
SchragASelaiCQuinnNHobartJ. Measuring health-related quality of life in patients with progressive supranuclear palsy. Neurocase. 2005;11(4):246–249.
19.
SchragASelaiCQuinnNLeesA. Measuring quality of life in PSP: the PSP-QoL. Neurology. 2006;67(1):39–44.
20.
FeggMKramerMBauseweinCBorasioG. Meaning in life in the Federal Republic of Germany: results of a representative survey with the Schedule for Meaning in Life Evaluation (SMiLE). Health Qual Life Out. 2007;5:59.
21.
LitvanIAgidYCalneD. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1–9.
22.
SprangersMSchwartzC. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48(11):1507–1515.
23.
MilneDMulderLBeelenHSchofieldPKempenGArandaS. Patients' self-report and family caregivers' perception of quality of life in patients with advanced cancer: how do they compare?Eur J Cancer Care (Engl). 2006;15(2):125–132.
24.
GolbeLOhman-StricklandP. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130(pt 6):1552–1565.
25.
UttlBSantacruzPLitvanIGrafmanJ. Caregiving in progressive supranuclear palsy. Neurology. 1998;51(5):1303–1309.
26.
PitceathlyCMaguireP. The psychological impact of cancer on patient’s partners and other key relatives: a review. Eur J Cancer Care. 2003;39(11):1517–1524.
27.
HodgesLHumphrisGMacfarlaneG. A meta-analytic investigation of the relationship between the psychological distress of cancer patients and their carers. Soc Sci Med. 2005;60(1):1–12.
28.
SchulzRCookTBeachS. Magnitude and causes of bias among family caregivers rating Alzheimer disease patients. Am J Geriatr Psychiatry. 2013;21(1):14–25.
